

Martin Ellis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/863137/publications.pdf>

Version: 2024-02-01

49
papers

832
citations

567281

15
h-index

552781

26
g-index

52
all docs

52
docs citations

52
times ranked

1364
citing authors

#	ARTICLE	IF	CITATIONS
1	Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies. <i>Frontiers in Endocrinology</i> , 2019, 10, 59.	3.5	123
2	Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via $\alpha_5\beta_1$ integrin in myeloma cells. <i>Oncotarget</i> , 2014, 5, 6312-6322.	1.8	61
3	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020, 95, 156-166.	4.1	53
4	An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2022, 139, 1098-1110.	1.4	46
5	Electronic patient identification for sample labeling reduces wrong blood in tube errors. <i>Transfusion</i> , 2019, 59, 972-980.	1.6	40
6	Autoimmune thyroid disease and antiphospholipid antibodies. , 2000, 64, 73-75.		38
7	Low thyroid hormone levels improve survival in murine model for ocular melanoma. <i>Oncotarget</i> , 2015, 6, 11038-11046.	1.8	34
8	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009042.	3.7	31
9	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. <i>Future Oncology</i> , 2021, 17, 1449-1458.	2.4	31
10	The Interplay Between Epithelial-Mesenchymal Transition (EMT) and the Thyroid Hormones- $\alpha_5\beta_1$ Axis in Ovarian Cancer. <i>Hormones and Cancer</i> , 2018, 9, 22-32.	4.9	29
11	Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer. <i>Scientific Reports</i> , 2017, 7, 16475.	3.3	27
12	Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias. <i>European Journal of Haematology</i> , 2018, 101, 297-304.	2.2	27
13	Severe juvenile vaginal bleeding due to Glanzmann's thrombasthenia: Case report and review of the literature. , 1998, 57, 225-227.		26
14	COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 3384-3393.	1.3	25
15	Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations. <i>International Orthopaedics</i> , 2014, 38, 169-175.	1.9	24
16	Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. <i>Trials</i> , 2021, 22, 323.	1.6	21
17	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. <i>Transfusion Medicine Reviews</i> , 2016, 30, 25-29.	2.0	15
18	Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B. <i>Haematologica</i> , 2016, 101, e303-e305.	3.5	14

#	ARTICLE	IF	CITATIONS
19	Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians. <i>PLoS ONE</i> , 2017, 12, e0171709.	2.5	14
20	Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre-Post Intervention Multicenter Pilot Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e449-e461.	0.4	13
21	Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2019, 102, 504-508.	2.2	13
22	The induction of myeloma cell death and DNA damage by tetrac, a thyroid hormone derivative. <i>Endocrine-Related Cancer</i> , 2018, 25, 21-34.	3.1	10
23	DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer. <i>Cancer Letters</i> , 2021, 501, 224-233.	7.2	10
24	Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. <i>Frontiers in Endocrinology</i> , 2018, 9, 775.	3.5	9
25	Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2019, 14, 1101-1112.	2.0	9
26	The identification of nuclear α 5 β 1 integrin in ovarian cancer: non-paradigmatic localization with cancer promoting actions. <i>Oncogenesis</i> , 2020, 9, 69.	4.9	9
27	Opposing effects of thyroid hormones on cancer risk: a population-based study. <i>European Journal of Endocrinology</i> , 2021, 184, 477-486.	3.7	9
28	D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. <i>Journal of Internal Medicine</i> , 2020, 287, 32-41.	6.0	8
29	Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality. <i>Endocrine-Related Cancer</i> , 2021, 28, 705-713.	3.1	8
30	The double benefit of Spalax p53: surviving underground hypoxia while defying lung cancer cells in vitro via autophagy and caspase-dependent cell death. <i>Oncotarget</i> , 2016, 7, 63242-63251.	1.8	8
31	Molecular insights into the transcriptional regulatory role of thyroid hormones in ovarian cancer. <i>Molecular Carcinogenesis</i> , 2018, 57, 97-105.	2.7	7
32	Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. <i>Oncogene</i> , 2021, 40, 6248-6257.	5.9	7
33	Azacitidine-lenalidomide (VLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS) – VLen-01 protocol. <i>Annals of Hematology</i> , 2016, 95, 1811-1818.	1.8	5
34	The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription. <i>Leukemia and Lymphoma</i> , 2017, 58, 1172-1177.	1.3	5
35	Enhanced expression of α 5 β 1 integrin in villus and extravillous trophoblasts of placenta accreta. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 1175-1183.	1.7	5
36	Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e351-e362.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Nuclear α 23 integrin expression, post translational modifications and regulation in hematological malignancies. <i>Hematological Oncology</i> , 2022, 40, 73-82.	1.7	3
38	Chemical and thyroid hormone profile of the bone marrow interstitial fluid in hematologic disorders and patients without primary hematologic disorders. <i>Hematological Oncology</i> , 2018, 36, 445-450.	1.7	2
39	Thrombophilia-Associated Factors in Patients with Spontaneous Osteonecrosis of the Knee. <i>Cartilage</i> , 2019, 10, 53-60.	2.7	2
40	Pregnancy and non-pregnancy related immune thrombotic thrombocytopenic purpura in women of reproductive age. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 187-193.	2.1	2
41	A Case of Chronic Lymphocytic Leukemia Complicated by Hemophagocytic Lymphohistiocytosis: Identifying the Aberrant Immune Response. <i>Journal of General Internal Medicine</i> , 2022, , 1.	2.6	2
42	A novel index using inflammatory markers improves the diagnosis of hemophagocytic lymphohistiocytosis in patients with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7563-7563.	1.6	1
43	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. <i>Blood</i> , 2014, 124, 3163-3163.	1.4	1
44	Anemia in Patients With Diabetes and Prediabetes With Normal Kidney Function: Prevalence and Clinical Outcomes. <i>Endocrine Practice</i> , 2022, 28, 129-134.	2.1	1
45	PREVALENCE AND CLINICAL SIGNIFICANCE OF HYPERCALCEMIA AT DIAGNOSIS IN DIFFUSE LARGE B CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 420-421.	1.7	0
46	Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group. <i>Acta Haematologica</i> , 2020, 144, 1-8.	1.4	0
47	Decision-Making in the Management of Venous Thromboembolism. <i>American Journal of Medicine</i> , 2021, 134, 317-325.	1.5	0
48	Serum soluble CD25 and ferritin in distinguishing patients with uncomplicated hematologic malignancies from patients with hematologic malignancies complicated by hemophagocytic lymphohistiocytosis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20072-e20072.	1.6	0
49	The utility of the novel optimized HLH inflammatory (OHI) index for predicting the risk for mortality and causes of death in lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7570-7570.	1.6	0